

Letter to the Editor



Comparing Neurofilament Light Chain Levels in Serum and Plasma

Hyuk Sung Kwon ,¹ Hyesun Lee ,¹ Young Seo Kim ,² Hojin Choi ,¹
Kyu-Yong Lee ,¹ Young Joo Lee ,¹ Eun-Hye Lee ,¹ Mina Hwang ,¹
Hyunhee Park ,¹ Seong-Ho Koh ¹

¹Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

²Department of Neurology, Hanyang University College of Medicine, Seoul, Korea



Received: Mar 22, 2023

Revised: Apr 14, 2023

Accepted: May 1, 2023

Published online: May 30, 2023

Correspondence to

Seong-Ho Koh

Department of Neurology, Hanyang University
College of Medicine, Guri Hospital, 153
Gyeongchun-ro, Guri 11923, Korea.
Email: ksh213@hanyang.ac.kr

© 2023 Korean Dementia Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Hyuk Sung Kwon

<https://orcid.org/0000-0002-2005-0988>

Hyesun Lee

<https://orcid.org/0000-0002-3141-9205>

Young Seo Kim

<https://orcid.org/0000-0002-7050-3426>

Hojin Choi

<https://orcid.org/0000-0002-9637-4423>

Kyu-Yong Lee

<https://orcid.org/0000-0001-8855-7513>

Young Joo Lee

<https://orcid.org/0000-0002-7531-9011>

Eun-Hye Lee

<https://orcid.org/0000-0002-0409-9859>

Mina Hwang

<https://orcid.org/0000-0002-5866-8906>

Hyunhee Park

<https://orcid.org/0000-0003-2367-799X>

Seong-Ho Koh

<https://orcid.org/0000-0001-5419-5761>

<https://dnd.or.kr>

Dear editor,

Neurofilament light chain (NfL) has been suggested as a blood-based biomarker for neuroaxonal injury.¹ Blood level of NfL is known to be increased in diverse neurological disorders, including ischemic stroke, demyelinating disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Alzheimer's disease.^{2,3} Both serum and plasma NfL levels are associated with smaller hippocampal volume, thinner cerebral cortex, and longitudinal cognitive decline.^{4,5} Depending on the study, serum or plasma NfL level was analyzed. Previous studies have reported a significant correlation between serum and plasma NfL levels.^{6,7} However, it is unclear whether such correlation is well maintained under specific conditions such as old age and those who are amyloid positive. Thus, the objective of this study was to investigate the association between serum and plasma NfL levels according to amyloid positivity.

Serum and plasma NfL levels of 38 participants (12 cognitively unimpaired, 18 mildly cognitively impaired, and 8 with dementia) were analyzed in this study. This study was approved by the Institutional Review Board of Hanyang University Guri Hospital (2018-01-015). Serum and plasma NfL levels were measured using an NF-Light Advantage assay (Quanterix, Boston, MA, USA, PN/103186) according to the Simoa Guide (Quanterix). Positron emission tomography scans were reviewed according to predefined regional cortical tracer uptake and brain amyloid plaque load (BAPL) scoring systems. A BAPL score of 1 was regarded as amyloid negative while BAPL scores of 2 and 3 were considered amyloid positive.⁸ Wilcoxon's rank sum test was used to compare paired NfL data. Correlation between serum and plasma NfL levels was determined using Spearman's rho. All statistical analyses were performed using the Statistical Package for the Social Sciences for Windows version 21.0 (SPSS Inc., Armonk, NY, USA).

Of the 38 participants, 50% (n=19) were women. Their mean (\pm standard deviation) age was 70.6 \pm 9.5 years (range, 52 to 88 years). Amyloid positivity was observed in 16 (42.1%) participants. NfL levels were higher in the plasma (median: 29.6 pg/mL; 25% interquartile range [IQR]: 22.8–43.4 pg/mL) than in the serum (median: 27.7 pg/mL; IQR: 20.2–35.0 pg/mL, $p < 0.001$). There was a strong correlation (Spearman's rho [r]=0.961) between serum and plasma NfL levels in the same participants (**Fig. 1A**). This strong correlation was consistently observed in female ($r=0.956$, $n=19$), male ($r=0.960$, $n=19$), amyloid-negative ($r=0.975$, $n=22$), and amyloid-positive ($r=0.938$, $n=16$) participants (**Fig. 1B-E**).




Fig. 1. Correlation between serum and plasma levels of neurofilament light chain in total (A), female (B), male (C), amyloid-negative (D), and amyloid-positive (E) participants. r: Spearman's rho correlation coefficient.

Conflict of Interest

Seong-Ho Koh, Editor-in-Chief, and Hyuk Sung Kwon, Assistant Editor of *Dementia and Neurocognitive Disorders*, were not involved in editorial evaluations or the decision to publish this article. The authors have no conflicts of interest to declare.

Author Contributions

Conceptualization: Kwon HS, Koh SH; Data curation: Lee EH; Investigation: Lee H, Kim YS, Choi H, Lee KY, Lee YJ, Lee EH, Hwang M, Park H; Methodology: Kwon HS, Lee H, Lee EH, Hwang M, Park H; Supervision: Kim YS, Choi H, Lee KY, Lee YJ, Koh SH; Writing - original draft: Kwon HS; Writing - review & editing: Koh SH.

The strong correlation between serum and plasma levels is in line with previous reports analyzing healthy donors⁹ or young patients with diverse neurological diseases (mostly multiple sclerosis).⁶ However, the median level of NfL was significantly higher in the serum than in the plasma in two previous reports.^{6,7} The reason for the difference between serum and plasma NfL levels is unclear. However, the current study showed that NfL levels in the serum were not always higher than those in the plasma. Additionally, the clinical significance of this difference might be low.⁷ In conclusion, there is a strong correlation between serum and plasma NfL levels regardless of amyloid positivity or sex. Both serum and plasma NfL levels are expected to be useful biomarkers for diverse neurodegenerative diseases.

REFERENCES

1. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gatteringer T, et al. Neurofilaments as biomarkers in neurological disorders. *Nat Rev Neurol* 2018;14:577-589. [PUBMED](#) | [CROSSREF](#)
2. Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising blood biomarkers for clinical use in Alzheimer's disease: a focused update. *J Clin Neurol* 2022;18:401-409. [PUBMED](#) | [CROSSREF](#)

3. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Alzheimers Dement (Amst)* 2019;11:730-743.
[PUBMED](#) | [CROSSREF](#)
4. Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. *JAMA Neurol* 2017;74:557-566.
[PUBMED](#) | [CROSSREF](#)
5. Lee EH, Kwon HS, Koh SH, Choi SH, Jin JH, Jeong JH, et al. Serum neurofilament light chain level as a predictor of cognitive stage transition. *Alzheimers Res Ther* 2022;14:6.
[PUBMED](#) | [CROSSREF](#)
6. Altmann P, Ponleitner M, Rommer PS, Haslacher H, Mucher P, Leutmezer F, et al. Seven day pre-analytical stability of serum and plasma neurofilament light chain. *Sci Rep* 2021;11:11034.
[PUBMED](#) | [CROSSREF](#)
7. Hviid CV, Knudsen CS, Parkner T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. *Scand J Clin Lab Invest* 2020;80:291-295.
[PUBMED](#) | [CROSSREF](#)
8. Syed YY, Deeks E. [(18)F]Florbetaben: a review in β -amyloid PET imaging in cognitive impairment. *CNS Drugs* 2015;29:605-613.
[PUBMED](#) | [CROSSREF](#)
9. Harp CT, Hendricks R, Fischer SK, Brumm J, Herman AH. Neurofilament light chain (NfL) levels in CSF, serum, and plasma of healthy donors using the Quanterix NfL Advantage Kit™ (P1.9-032). *Neurology* 2019;92:P1.9-032.